Whether a salicylic acid body serum is regulated as a cosmetic or an OTC drug in the United States depends almost entirely on the concentration and the product claims you make. The FDA's OTC drug monograph system (21 CFR Part 333 for anti-dandruff, 21 CFR Part 330 for acne) is the governing framework here, and salicylic acid sits inside both.
For leave-on body products making acne claims, salicylic acid is an FDA-recognized OTC active ingredient at concentrations of 0.5% to 2%. If your formula hits exactly 2% SA in a leave-on body serum and you make any acne-related claim on the label or marketing materials — things like 'clears body acne,' 'reduces breakouts,' 'unclogs pores' — the product is an OTC drug. That means it requires a Drug Facts panel formatted to FDA specifications, it must follow the OTC monograph's directions and warnings, and your manufacturing facility must comply with pharmaceutical-grade cGMPs (21 CFR Parts 210/211), not just cosmetic GMPs.
If you formulate at, say, 1.5% SA and make no drug claims — instead positioning the serum around 'smooth skin texture' or 'exfoliation' without referencing acne — you are operating as a cosmetic under 21 CFR Part 701. This is a much lighter regulatory burden: no Drug Facts panel, no drug-facility registration requirement, and standard cosmetic labeling rules apply.
The critical mistake many indie founders make is launching at 2% SA with cosmetic-only labeling, then making acne claims in their Instagram captions or website copy. The FDA reviews marketing materials holistically — off-label digital claims can cause an otherwise compliant cosmetic label to be viewed as an unapproved new drug.
For the EU, salicylic acid in rinse-off products is permitted at up to 3% as a cosmetic ingredient under Annex III of EC Regulation 1223/2009, and in leave-on products at up to 2%. Leave-on products must carry the warning 'Contains Salicylic Acid' and are not recommended for use by children under 3. There is no equivalent to the US OTC drug framework in the EU — claims are governed by cosmetic claim substantiation rules (Regulation 655/2013).
Transexamic acid has no specific regulatory restriction in either the US or EU at cosmetic use concentrations (typically 1–3%), and is classified as a cosmetic ingredient in both markets, making the regulatory risk profile of a TXA + SA serum largely driven by the SA concentration and claims strategy.
A cosmetic chemist or regulatory consultant should review your label and claims before you go to production. Many cosmetic contract manufacturers accessible through AJ Cosmo Labs have in-house regulatory teams or preferred consultants who can flag these issues early.
Ingredients in this answer: Salicylic Acid
Read the full guide on Private Label Tranexamic & Salicylic Acid Body Serum →